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INTRODUCTION Background
Atrial fibrillation is characterized by disorganized atrial electrical depolarization leading to an irregular and rapid pulse rate. In the emergency department (ED), physicians often manage patients with either recent-onset or permanent (chronic) atrial fibrillation. 1 In the case of permanent atrial fibrillation, cardioversion has previously failed or clinical judgment has led to a decision not to pursue cardioversion, with ED care focusing on rate control. 2 When atrial fibrillation terminates spontaneously within 7 days of recognized onset, it is designated paroxysmal; when sustained beyond 7 days, atrial fibrillation is designated persistent. Atrial flutter is an arrhythmia with similar pathophysiology that is characterized by rapid, regular atrial depolarizations at a characteristic rate of approximately 300 beats/min and presents with various degrees of atrioventricular block. Atrial flutter is less common than atrial fibrillation but has similar management issues in the ED, and most patients with atrial flutter also have episodes of atrial fibrillation. Our focus is on symptomatic patients with recent-onset atrial fibrillation and flutter, ie, those with episodes of atrial fibrillation or atrial flutter (first detected, recurrent
Editor's Capsule Summary
What is already known on this topic Recent-onset atrial fibrillation and flutter are commonly treated in the emergency department (ED).
What question this study addressed
What happens to patients with these 2 rhythms in a setting in which ED cardioversion attempts (electrical and pharmacologic) are common?
What this study adds to our knowledge In a 1,091-subject cohort from 6 Canadian EDs, 80.1% converted to sinus rhythm. Adverse effects in the next 30 days included only 1 stroke and no deaths.
How this is relevant to clinical practice ED cardioversion of these patients often succeeds without harm, buttressing the argument for embracing this practice.
paroxysmal, or recurrent persistent) in which the onset is less than 48 hours and cardioversion is an option. Recentonset atrial fibrillation and flutter are the most common acute arrhythmia cases requiring care in the ED.
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Importance
Variation in practice within EDs has been well described and reflects a lack of high-quality evidence to guide the acute management of recent-onset atrial fibrillation and flutter. [6] [7] [8] Standard textbooks and guidelines fail to offer clear evidencebased direction for physicians treating recent-onset atrial fibrillation and flutter. [9] [10] [11] [12] Particularly controversial is the issue of using rhythm control or rate control. [13] [14] [15] [16] The large Atrial Fibrillation Follow-up Investigation of Rhythm Management and AF-CHF trials compared rate and rhythm control for patients with mostly recurrent, persistent atrial fibrillation but did not explore the optimal management for ED recent-onset atrial fibrillation and flutter patients presenting within 48 hours of onset. 17, 18 In the United States, patients are often admitted to the hospital under the cardiology service or discharged home after rate control only. 19 In Canada, emergency physicians are much more likely to follow an aggressive antiarrhythmia treatment approach using pharmacologic cardioversion or electrocardioversion. 6, 8, 20 They perceive that this strategy has significant benefits for patients: immediate return to normal activities without the need for hospital admission or need for treatment with rate control and oral anticoagulant drugs. Two sites have described several cohorts of patients successfully treated with rhythm control, with good results. 4, [21] [22] [23] Other ED studies of rhythm control for recent-onset atrial fibrillation and flutter have been small or did not include both pharmacologic and electrocardioversion as an option. 19, [24] [25] [26] [27] 
Goals of This Investigation
We are not aware of previous studies that prospectively followed recent-onset atrial fibrillation and flutter patients after ED disposition. We sought to fill this knowledge gap about the outcomes and adverse events that might occur in such patients after a sentinel ED visit, regardless of initial management or disposition. In particular, our goal was to describe ED management and then follow patients prospectively for 30 days to determine clinical outcomes, use of health care resources, use of oral anticoagulants, and adverse events. Finally, we wished to evaluate potential risk factors for these adverse events to better understand how to prevent them.
MATERIALS AND METHODS Study Design and Setting
We conducted a prospective cohort study in 6 Canadian academic hospital EDs.
Selection of Participants
We attempted to enroll consecutive patients presenting with an episode of recent-onset atrial fibrillation and flutter, in which symptoms required urgent management and in which pharmacologic or electrocardioversion was an option. Specifically, we included patients with a clear history of onset within 48 hours, or a clear history of onset within 7 days and who had received adequate anticoagulation, or a clear history of onset within 7 days and no left atrial thrombus on transesophageal echocardiography. We did not exclude patients who required admission or who converted spontaneously to sinus rhythm before treatment.
We excluded patients who had been previously enrolled, with permanent or persistent atrial fibrillation, or whose primary presentation was for another condition such as (1) acute coronary syndrome presenting with chest pain and acute ischemic changes on ECG; (2) congestive heart failure with severe shortness of breath requiring immediate intravenous diuretic, nitrates, or bilevel positive airway pressure; (3) pneumonia with temperature greater than 38.5 C (101.3 F), respiratory symptoms, and receiving antibiotics in the ED; (4) pulmonary embolism presenting with chest pain or shortness of breath; and (5) sepsis with infection and 2 or more systemic inflammatory response syndrome criteria.
Patients were identified prospectively in the ED and then followed by telephone interviews.
Patients gave consent to participate in the study, as approved by the respective hospital research ethics boards.
Methods of Measurement and Data Collection and Processing
The sources of data were the ED health record (including nursing and physician notes), hospital electronic records (clinical, laboratory, and imaging), ED enrollment form, clinic records, self-administered patient questionnaire, follow-up telephone interviews, and provincial coroners' records. We collected extensive demographic and clinical patient data, details of ED treatment, outcomes, and disposition. The chest radiography interpretations were those of certified radiologists who had no knowledge of the study protocol. We then followed patients for 30 days to determine subsequent ED and physician visits, investigations and prescriptions, and need for cardioversion or admission. Site study staff were individually trained and monitored by a central study coordinator who reviewed source documents for the accuracy of the data submitted.
Outcome Measures
We were particularly interested in the occurrence of serious adverse events and their relationship with atrial fibrillation or atrial flutter. We created a composite outcome, serious event, that included the following within 30 days: death, stroke, acute coronary syndrome, heart failure, subsequent hospital admission related to atrial fibrillation or atrial flutter, and subsequent need for ED electrocardioversion.
Primary Data Analysis
Management, ED clinical outcomes, 30-day outcomes, and health care resource use were presented descriptively as appropriate for continuous, ordinal, and categorical outcomes. We classified the following as adverse events: death, stroke, acute coronary syndrome, acute heart failure, subsequent hospital admission related to atrial fibrillation or atrial flutter, and subsequent need for ED electrocardioversion. We evaluated the univariate association of 20 clinical and demographic factors with adverse events, using t tests, Mann-Whitney U tests, and c 2 tests for continuous, ordinal, and categorical variables, respectively. We then conducted multivariate logistic regression analyses to identify independent predictors associated with adverse events. Model building proceeded with backward elimination selection P<0.1. The following independent variables were tested in the multivariate models: age, CHADS2 score, previous stroke, atrial fibrillation versus atrial flutter, hours since onset of atrial fibrillation and flutter, ischemia on ECG, congestion on chest radiograph, pulse rate at disposition from ED, and rhythm at disposition with mode of conversion (spontaneous, pharmacologic, or electrical). We estimated that approximately 1,000 patients would yield at least 100 adverse events, allowing us to evaluate at least 10 predictor variables in the multivariate modeling.
RESULTS
Characteristics of Study Subjects
We enrolled 1,091 of 1,120 eligible patients between June 2010 and May 2012 at 6 hospital sites ( Figure) . Twenty-nine patients were missed, usually after hours, but we could detect no bias in patient selection. By review of electronic health and coroners' records, we were able to ascertain the outcomes of all patients.
These recent-onset atrial fibrillation and flutter patients were younger than typical permanent atrial fibrillation patients, with a mean age of 63.9 years (Table 1) , although 17.2% were aged 80 years or older. On arrival to the ED, 84.7% of patients were in atrial fibrillation and 15.3% in atrial flutter, the mean duration of symptoms was 7.7 hours, and 65.0% had previous episodes of recent-onset atrial fibrillation and flutter. Of 630 patients (57.8%) with a CHADS2 score of 1 or more, only 202 (32.1%) were receiving warfarin. Although 73.6% of patients had troponin levels and 29.9% had thyroid-stimulating hormone levels measured, only 3 underwent transesophageal echocardiography while in the ED.
Main Results
Patients were most likely to be primarily treated with electrocardioversion or pharmacologic cardioversion (72.8%), with intravenous procainamide being by far the most common drug used (Table 2) . Electrocardioversion (97.9%) and sedation (98.3%) were almost always provided by the emergency physician. Heparin was rarely administered in the ED (4.6%). Adverse events with cardioversion were uncommon and usually transient (Table 3) . Only 9.0% of patients were admitted and only 19.9% were not in sinus rhythm at discharge (Table 4) . Although physician follow-up was routinely recommended, rarely was an outpatient echocardiogram ordered (8.2%) or oral anticoagulants prescribed (4.8%).
We successfully followed patients for 30 days and noted that 27.9% returned to the ED and 15.4% returned for an issue directly related to atrial fibrillation or atrial flutter (Table 5) . By 30 days, 50.7% of patients had consulted a physician and only small numbers of patients had received prescriptions for warfarin (4.5%) or novel oral anticoagulants (4.1%). We estimate that by 30 days, only 49.3% of patients with CHADS2 score of 1 or more were receiving oral anticoagulants.
Overall, 10.5% of patients had experienced an adverse event, but there were no deaths related to atrial fibrillation or atrial flutter and there was 1 stroke (ischemic) ( Table 6 ). Four patients died because of renal and heart failure, cancer (2) , and respiratory failure. The patient who had a stroke was an 81-year-old woman who was receiving warfarin with international normalized ratio 2.3 and who spontaneously converted to normal sinus rhythm while in the ED 23 days before. Within 30 days, 6.5% of patients required electrocardioversion in the ED (versus 0.9% in a clinic) and 3.2% of patients had returned and required admission for atrial fibrillation or atrial flutter. There was variation among The CHADS2 score ranges from 0 to 6.
sites in treatment strategies and outcomes (Table E1 , available online at http://www.annemergmed.com).
We found many variables strongly associated with adverse events on univariate analysis (Table 7) . Further analysis by multivariate techniques revealed 3 patient-related variables and 1 management-related variable that were independently associated with adverse events ( Figure E1 and Table E2 , available online at http://www.annemergmed.com). Increasing risk for adverse event were hours from onset of atrial fibrillation and flutter (odds ratio 1.03/hour; 95% confidence interval [CI] 1.01 to 1.05), history of stroke or transient ischemic attack (TIA) (2.09; 95% CI 1.01 to 4.36), and pulmonary congestion on chest radiograph as reported by radiologists (7.37; 95% CI 2.40 to 22.64). In regard to discharge rhythm, patients who left the ED in sinus rhythm were much less likely to experience an adverse event (P<.001), with those converted pharmacologically having the lowest odds ratio (0.23; 95% CI 0.08 to 0.64). For the overall model, Hosmer and Lemeshow goodness-of-fit P value was .84 and the c statistic was 0.680.
LIMITATIONS
We recognize that this observational cohort study had several limitations, including the fact that not all eligible patients were enrolled in the study. However, only 29 patients (2.6%) were missed and this low number is unlikely to contribute substantive patient selection bias. We acknowledge that we did not have follow-up ECG tracings for the majority of patients but are confident that patients with a recurrence of atrial fibrillation and flutter would have been identified by a return visit to the ED. We were able to ascertain survival status on all patients. We could not model correlates of death and stroke alone because of the rarity of these events. Consequently, we chose to define adverse events as a composite of clinically relevant outcomes. Strengths of the study include detailed prospective follow-up, a large cohort from multiple sites, and detailed data collection. *No novel oral anticoagulants were used in the ED during the study period.
DISCUSSION
We believe this to be the largest multicenter prospective study to evaluate the outcomes of recent-onset atrial fibrillation and flutter patients managed in the ED. Our study found that such patients are younger than those reported as having permanent or persistent atrial fibrillation. In our Canadian sites, the majority of patients were safely treated with restoration of sinus rhythm by pharmacologic cardioversion with intravenous procainamide or electrocardioversion and sedation provided by the emergency physician. Adverse events with cardioversion were uncommon and most patients were discharged in sinus rhythm. Prescription of oral anticoagulants in the ED was surprisingly low, considering that more than 50% of patients had a CHADS2 score of 1 or more and only 25% were currently receiving warfarin. Approximately 10% of patients experienced an adverse event within 30 days of the ED visit, with no deaths related to atrial fibrillation or atrial flutter and 1 stroke. The key findings of this study are the identification of potential risk factors for subsequent adverse events. Patient-related risk factors are longer time from onset of arrhythmia, history of stroke or TIA, and pulmonary congestion on chest radiograph. We also identified an important treatment risk factor, with patients who left the ED in sinus rhythm being much less likely to experience an adverse event. The lowest odds ratio was for patients converted pharmacologically. These potential risk factors should be carefully considered by physicians managing recent-onset atrial fibrillation and flutter in the ED.
We are aware of no prospective studies that were able to link specific ED management strategies with patient outcomes in a focused population of recent-onset atrial fibrillation and flutter patients. We identified 13 studies of ED recent-onset atrial fibrillation and flutter management involving restoration of sinus rhythm by drugs or electrocardioversion. These studies used a variety of methodologies (health records review, 4, 21, 22, 27, 28 prospective cohort, [29] [30] [31] [32] and randomized trial 19, 24, 25, 33 ) and only 2 prospectively followed patients outside the hospital. Decker et al 19 followed 153 US patients for up to 6 months and found relatively few adverse events. Bellone et al 33 followed 247 Italian patients but reported rhythm only at 60 days. Scheuermeyer et al 22, 23 conducted several retrospective Canadian health records reviews to evaluate outcomes of recent-onset atrial fibrillation and flutter patients at 30 days and 1 year and also found relatively few adverse events. They also identified underuse of oral anticoagulants by emergency physicians. 34 In another retrospective study, Atzema et al 35 noted the low physician follow-up rate within 7 days of an ED visit. None of these studies attempted to identify risk factors for adverse events. Atzema et al 36 identified a number of factors associated with mortality in a large database study of nonspecific atrial fibrillation patients with a very low ED cardioversion rate (15%). Barrett et al 37 created a predictive model aid for adverse events, but the findings are not applicable to the Canadian setting in that 85% of patients were admitted and there were no data on ED management strategies.
There are few data on the incidence of stroke after an ED visit for atrial fibrillation. 38 Airaksinen et al 39 reported a 7-year review of patients who were successfully cardioverted from atrial fibrillation with onset less than 48 hours, in a cardiology clinic, and who had neither longterm oral anticoagulation nor periprocedural heparin therapy. 20 Of 5,116 successful cardioversions in 2,481 patients, 0.7% of patients developed thromboembolic events within 30 days (median 2 days). Noted risk factors were similar to those from the CHADS2 score.
This study reveals some variation in management among sites but confirms the safety and effectiveness of an aggressive pharmacologic or electrocardioversion strategy in the ED, with few patients requiring admission. We encourage physicians to seriously consider rhythm control rather than rate control in the ED because this strategy immediately returns patients to their normal state and daily activities and avoids the burden of hospitalization.
Although patient outcomes were very good, we were concerned about the infrequent prescription of oral anticoagulants by emergency physicians for the many patients with a CHADS2 score of 1 or more. This is contrary to recommendations of the Canadian Cardiovascular Society. 40, 41 The main purpose of anticoagulation for at-risk recent-onset atrial fibrillation and flutter patients is to reduce their long-term risk of stroke, not just in the immediate postcardioversion period. The current recommendations include prescription of oral anticoagulants (warfarin or novel oral anticoagulants) to recent-onset atrial fibrillation and flutter patients who are aged 65 or older or have 1 or more CHADS2 risk factors. Less than half of patients with a CHADS2 score of 1 or more were receiving oral anticoagulants 30 days after the sentinel ED visit. We believe that this therapy should be initiated in the ED because many patients have trouble accessing early follow-up care and because many primary care physicians may not be familiar with these recent guidelines. 42 Clearly, all recent-onset atrial fibrillation and flutter patients must have their CHADS2 factors and bleeding risk evaluated in the ED.
Our findings provide additional tools to physicians who manage recent-onset atrial fibrillation and flutter and who should recognize additional risk of adverse events for patients whose presentation is delayed, have had previous stroke or TIA, or have evidence of active heart failure. We suggest early follow-up for these patients. Our findings suggest that patients fare better when they leave the ED in sinus rhythm, and this should provide further evidence for physicians who have been reluctant to cardiovert. We recognize that our recommendations are not the result of a randomized trial comparing rate versus rhythm control for recent-onset atrial fibrillation and flutter. Cardioversion is now so widely used in Canadian EDs that it would be difficult, if not impossible, to enroll a large enough sample size to test for superiority with clinical outcomes.
Much research is still required to determine the safest and most effective management strategies for recent-onset atrial fibrillation and flutter patients. For example, there is clinical equipoise in Canada about whether rhythm control in the ED should commence with pharmacologic or electrocardioversion. We recommend further evaluation of the effect of recent-onset atrial fibrillation and flutter riskstratification and cardioversion for all patients in the ED. This multicenter prospective study found that although most recent-onset atrial fibrillation and flutter patients were treated aggressively in the ED, there were few serious outcomes within 30 days. Physicians underprescribed oral anticoagulants. We identified potential patient-specific risk factors for adverse events, including longer duration from onset of arrhythmia, previous stroke or TIA, and congestion on chest radiograph. We also identified that patients who left the ED in sinus rhythm were much less likely to experience an adverse event, with the lowest risk being for those converted pharmacologically. We encourage consideration of these risk factors and use of cardioversion for most recentonset atrial fibrillation and flutter patients in the ED. Figure E1 . Adjusted odds ratios with 95% CIs for factors associated with 30-day adverse events. Hosmer and Lemeshow goodness-of-fit P value .84; c statistic¼0.680. Table E2 . Independent predictors of serious adverse events as determined by stepwise logistic regression analysis for 1,091 recent-onset atrial fibrillation and flutter patients. 
